1. 1407PDerived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (23rd October 2018) Authors: Mezquita, L; Arbour, K; Auclin, E; Saravia, D; Rizvi, H; Hendriks, L; Planchard, D; Park, W; Nadal, E; Ruffinelli Rodriguez, J C; Ponce, S; Audigier-Valette, C; Marilniello, A P; Zalcman, G; Majem, M; Schiavone, G; Dingemans, A-M C; Lopes, G; Hellmann, M D; Besse, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817. (15th December 2019) Authors: Barlesi, F; Audigier-Valette, C; Felip, E; Ciuleanu, T-E; Jao, K; Rijavec, E; Urban, L; Aucoin, J-S; Zannori, C; Vermaelen, K; Frontera, O Arén; Ready, N; Curioni, A; Linardou, H; Poddubskaya, E; Fischer, J R; Pillai, R; Li, S; Acevedo, A; Paz-Ares, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis. (15th December 2019) Authors: Paz-Ares, L; Ciuleanu, T E; Yu, X; Salman, P; Pluzanski, A; Nagrial, A; Havel, L; Kowalyszyn, R; Audigier-Valette, C; Wu, Y-L; Borghaei, H; Hellmann, M D; Brahmer, J; Reck, M; Ramalingam, S; Zhang, L; Bhagavatheeswaran, P; Nathan, F E; O'Byrne, K J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. (17th December 2018) Authors: Reck, M; Vicente, D; Ciuleanu, T; Gettinger, S; Peters, S; Horn, L; Audigier-Valette, C; Pardo, N; Juan-Vidal, O; Cheng, Y; Zhang, H; Shi, M; Wolf, J; Antonia, S J; Nakagawa, K; Selvaggi, G; Baudelet, C; Chang, H; Spigel, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗